NR4A1 and breast carcinoma: USCAP guidelines for hormonal receptor testing in breast cancer now recommend the report of cancers that have low (1–10%) ER-positivity to distinguish from those with higher ER expression levels in recognition of the limited data on responsiveness of the former group to endocrine therapy [36].